Novel Treatment Advances and Approaches in the Management of Advanced Renal Cell Carcinoma (RCC)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 10, 2018 to June 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Exelixis and Novartis Pharmaceuticals

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. The prognosis for any treated renal cell cancer patient with progressing, recurring, or relapsing disease is poor, regardless of cell type or stage and almost all patients with advanced renal cell cancer are incurable. Fortunately, emerging treatment options, including targeted therapies such as tyrosine kinase inhibitors (TKIs), are being integrated into the advanced RCC treatment paradigm. These newer options individualize therapy for patients with advanced RCC who have progressed on prior therapies, ultimately improving patient outcomes and quality of life. However, the question and selection of further treatment depends on many factors, including previous treatment and site of recurrence, as well as individual patient considerations. In addition, clinicians must analyze and apply evidence-based data and implement updated strategies to manage side effects of newer agents in order to select an appropriate treatment.

Upon Completion of this activity, participants will be able to:

  • Describe the mechanistic rationale for applying novel targeted strategies in the setting of advanced renal cell carcinoma (RCC)

  • Evaluate the use of tyrosine kinase inhibitors (TKIs) in the management of patients with advanced RCC

  • Select appropriate therapy using current clinical data, disease risk, and patient characteristics and preferences to provide optimal outcomes for individual patients with advanced RCC

  • Explore evolving targeted treatment approaches to overcome anti-angiogenic resistance in the management of RCC

  • Analyze strategies to manage adverse events of newer agents to minimize effects on quality of life and maintain efficacy for patients with RCC

Faculty: Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center


Dr. Figlin serves on an advisory board for Pfizer, serves as a consultant to CB Therapeutics and Pfizer, and receives research support from Argos, Bristol-Myer Squibbs, GlaxoSmithKline, and Peloton. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Exelixis and Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue